Strategies for the Treatment of Infantile Soft Tissue Sarcomas With BCOR Alterations
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jan 2023 · 1 min read
In brief
In brief
This multi-institutional retrospective study examines treatment outcomes for nine infants with BCOR-altered soft tissue sarcomas, including primitive myxoid mesenchymal tumor of infancy and undifferentiated round cell sarcoma. Eight of nine patients achieved no evidence of disease status using anthracycline-based chemotherapy regimens combined with radiotherapy, demonstrating improved outcomes compared to historical reports.
Written by the GCMD Library team from the article.
Statements in this article
BCOR alterations are described in ultra-rare infantile soft tissue sarcomas including primitive myxoid mesenchymal tumor of infancy and undifferentiated round cell sarcoma.
Nine patients aged 6 weeks to 15 months with BCOR-rearranged soft tissue sarcomas were identified in this multi-institutional retrospective study.
One tumor carried a BCOR::CCNB3 fusion, whereas 7 tumors harbored internal tandem duplication of BCOR.
Four patients underwent upfront surgery with residual disease that progressed locally after a median of 2.5 months.
Locoregional recurrences were observed in hybrid morphology patients, and the undifferentiated round cell sarcoma case recurred with brain metastases.
Complete radiographic responses after chemotherapy were achieved in patients treated with vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide.
Complete radiographic responses after chemotherapy were achieved in patients treated with vincristine/doxorubicin/cyclophosphamide alternating with cyclophosphamide/etoposide (regimen I).
Complete radiographic responses after chemotherapy were achieved in patients treated with ifosfamide/carboplatin/etoposide.
Seven patients received radiotherapy.
With a median of 23.5 months off therapy, 8 patients are with no evidence of disease.
Observation was inadequate for the management of untreated postsurgical residual disease in this cohort.
Tumors demonstrated chemosensitivity with anthracycline-based regimens.